

## FORM 7

### MONTHLY PROGRESS REPORT

Name of CNQ Issuer: \_\_\_\_\_ Immunall Science Inc. \_\_\_\_\_ (the "Issuer").

Trading Symbol: GNS \_\_\_\_\_

Number of Outstanding Listed Securities: 38,565842 \_\_\_\_\_

Date: September 7th, 2010. \_\_\_\_\_

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNQ Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNQ.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNQ Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.
2. Provide a general overview and discussion of the activities of management.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or

- production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
  5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
  6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
  7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship..
  8. Describe the acquisition of new customers or loss of customers.
  9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
  10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
  11. Report on any labour disputes and resolutions of those disputes if applicable.
  12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
  13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
  14. Provide details of any securities issued and options or warrants granted.

<b>Security</b>	<b>Number Issued</b>	<b>Details of Issuance</b>	<b>Use of Proceeds<sup>(1)</sup></b>

*(1) State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.
16. Provide details of any changes in directors, officers or committee members.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The company was under a Management Cease Trade Order due to late filing of the Company's audited Financial Statements and Management and Discussion and Analysis. The Audited Financials and the Management Discussion and Analysis were filed with the Alberta Securities Commission and the British Columbia Securities Commission. The Management Cease Trade Order has now been lifted.

On the 22<sup>nd</sup> of May, Immunall Science Inc. announced that it signed an exclusive distributorship agreement with Infinity Science Corporation ("Infinity") of Canada. The agreement provides Infinity with the exclusive rights to market Immunall's patented immune enhancing product ginsē™ throughout Canada.

Dan Robertson was hired as "Operations Manager" June 2, 2008 for Immunall Science Inc.

On the 21<sup>st</sup> of July, Immunall Science Inc. announced that it signed an exclusive distributorship agreement with Cold and Flu Response LLC of Boulder Colorado. The agreement provides Cold and Flu Response with exclusive rights to market Immunall's patented immune enhancing product ginsē™ throughout the U.S.

Immunall Science Inc announced in September that one of it's Directors, Mr. Larry Shaben had passed away.

Immunall Science Inc. held it's annual General Meeting September 16<sup>th</sup>, 2008. All resolutions brought forth were passed including the election of new Director, Mr Craig McLennan.

The Company announced on July 21, 2008 that it has signed an exclusive distributorship agreement with Cold and Flu LLC. of Boulder Colorado, USA. Unfortunately, due to the current financial situation in the USA, Cold and Flu LLC has been unable to secure the necessary funds to finance their product launch and as a consequence the project has been deferred.

It was announced through a press release on December 18<sup>th</sup>, 2008. That Immunall Science Inc. signed an exclusive distributorship agreement with 7060173 Canada Ltd. The agreement provides 7060173 Canada Ltd. to market Immunall's patent immune enhancing product ginsē™ throughout Serbia, Croatia, Montenegro, Bosnia, Herzegovina and Macedonia.

The Audited Annual Financials and Management Discussion and Analysis were filed with the appropriate Provincial Securities Commissions and posted on SEDAR and SEDI on the 30<sup>th</sup> of April, 2009.

A Directors Meeting was held on the 12<sup>th</sup>, of August, 2009 at the office of Immunall Science Inc. at 10979-127st, Edmonton Alberta. It was motioned by Mr David Rogers, CEO of Immunall Science that the Board elect Mr. Jim Bruce of Boulder Colorado, as a Director to fill the vacant position. The vote was carried unanimously by the Board and Mr. Bruce was elected pending the submission of his personal information to the CNSX and Provincial Securities Commissions.

Mr. Jim Bruce has since declined the position of Director for Immunall Science Inc. and the position still remains vacant.

At a Directors meeting held March 31<sup>st</sup>, 2010. A motion was made by Mr. Frank Phillet, COO of Immunall Science Inc to elect Mr. Bret Smith as a Director with ISI to fill the vacant Director position. The vote was carried unanimously by the Board and Mr. Smith was elected pending the submission of his personal information to the CNSX and Provincial Securities Commissions.

Mr. David Rogers resigned from the board of Directors with Immunall Science on May15th, 2010. This leaves one vacant Director position with the board of Directors with Immunall Science Inc.

Immunall Science Inc. received a cease trade order from the Alberta Securities Commission as well as the British Columbia Securities Commission, for not filing its Annual Audited Financials for 2009, and its first quarter financials and MD and A. The Management of Immunall Science are currently working to rectify this.

As mentioned in a press release dated June 2<sup>nd</sup>, 2010, Immunall has entered into an agreement with an arm's length party to borrow up to \$25,000. The proceeds from the loan will be used for working capital to, among other things, complete the audit of Immunall's annual financial statements. Management of Immunall is also investigating a range of strategic options available with a view to maximizing shareholder value. Management does not intend to disclose developments with respect to the strategic review process unless and until the Board of Directors has approved a definitive transaction or strategic option.

The cease trade order was revoked from the Alberta, British Columbia and Ontario Securities Commissions on August 16<sup>th</sup>, after Immunall Science Inc. filed its audited financials for the year ending December 31<sup>st</sup>, 2009. The late interim financials for the first quarter of 2010, were also filed at this time.

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNQ that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNQ Requirements (as defined in CNQ Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 7<sup>th</sup>, 2010..

M. Frank Phillet  
Name of Director or Senior  
Officer

*" M. Frank Phillet"*  
Signature  
Chief Operating Officer  
Official Capacity

<b>Issuer Details</b>		For Month	Date of Report
Name of Issuer		End	YY/MM/D
Immunall Science Inc.		August	10/09/07
Issuer Address			
10979,127st			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Edmonton, Alberta, T5M-0T1		(780)421-9262	(780)452-4229
Contact Name		Contact Position	Contact Telephone No.
Frank Phillet		COO	(780)452-4229
Contact Email Address		Web Site Address	
info@ginse.ca		www.ginse.ca	

---

**FORM 7 – MONTHLY PROGRESS REPORT**

May 08, 2004  
Page 7

